|
|
 |
|
Viewing report
|
|
|
|
Angiogenesis Modulators
RI Technologies, Jan 2008, Pages: 174
This market insight report on Angiogenesis Modulators studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, dermatology, ophthalmology, rheumatology and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. The study includes estimates and projections for the total global angiogenesis therapeutic products market.
Global market for Angiogenesis therapeutic products is projected to reach about US$ 22 billion by 2012. Angiogenesis is the formation of new capillary blood vessels and plays an important role in several physiological processes such as wound repair, ovulation, embryonic development, and myocardium generation. With angiogenesis inhibitors showing great promise in reducing malignant tumors in rats, the market potential has greatly increased for therapeutic products in disease areas such as cancer, cardiovascular diseases, ophthalmic diseases, skin diseases, rheumatoid arthritis, and other angiogenesis based diseases.
Angiogenesis research has become one of the most interesting fields in biomedical areas. Cancer is the most prominent area for research with maximum number of drugs being targeted in this disease area. The tumors of cancer cannot survive without the existence and development of new blood vessels. This offers an important scope for researchers to restrict the cancer cells from expanding by restricting the formation of new blood vessels. Research on synthetic and natural angiogenesis inhibitors is also underway. The United States is the leading market for angiogenesis therapeutic products followed by Europe and Asia Pacific. Asia Pacific and Latin American markets are emerging markets with leading pharmaceutical companies outsourcing drug development and clinical trials in these developing regions.
Countries Covered:
United States
Europe
Germany
United Kingdom
France
Switzerland
Rest of Europe
Asia-Pacific
Japan
Rest of Asia-Pacific
Latin America
Rest of World
Customers who bought this item also bought
Angiogenesis Modulators: Strategies for Drug Discovery
Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report
Drug Targets for Breast Cancer
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Breast Cancer Therapeutics - Global Strategic Business Report
U.S. Diabetes Pipeline Outlook
Colorectal Cancer (CRC) Therapeutics - Global Strategic Business Report
Ovarian Cancer Therapeutics - Global Strategic Business Report
|
|
|
|
